Grand Pharma’s Innovative Product for Liver Tumors, Y-90, Is Commercialized in Mainland China, Empowering "Nuclear Power" to The Company’s Performance
- Written by The Chronicle
HONG KONG SAR - Media OutReach - 20 June 2022 - On 19 June, the technology innovation pharmaceutical company, Grand Pharmaceutical Group Limited (stock code: 0512.HK)’s global innovative product, SIR-Spheres® Y-90 microsphere injection for the treatment of liver malignant tumors, was officially commercialized in Mainland China.